1809794-70-4

Biological Activity: GNE-140 is a racemic mixture of (R)-GNE-140 (HY-100742A) and (S)-GNE-140 (HY-100742B), and it is also the racemate known as GNE-140 racemate (HY-100742). GNE-140 is an LDH inhibitor with IC₅₀ values of 0.003 μM and 0.005 μM against LDHA and LDHB/LDHC, respectively, and also inhibits recombinant human LDH5. GNE-140 reduces lactate production in MIA PaCa-2 cells, inhibits cell proliferation, decreases glucose uptake, and elevates ROS levels, reprogramming cellular metabolic flux toward glycolysis and the pentose phosphate pathway. GNE-140 induces acquired resistance mediated by the AMPK-S6K pathway. GNE-140 inhibits the proliferation of breast cancer cells such as MDA-MB-231, inhibits LDH activity and lactate production in eye organoids, and interferes with early embryonic development in mice. GNE-140 combined with arabinoxylan attenuates intestinal inflammatory injury and improves gut microbiota diversity in choline-fed mice. GNE-140 can be used in research related to cancers such as breast cancer, ocular organ development, embryogenesis, and intestinal inflammatory diseases^{[1][2][3][4][5][6]}.